Open AccessWeekly vs. 3‑weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
Author(s) -
LeeAnn Geraghty,
Thomas E. Schultz,
Sarah Hoffman,
Kyle Porter,
Majd Issa,
Vidhya Karivedu,
Marcelo Bonomi
Publication year - 2021
Publication title -
molecular and clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 7
eISSN - 2049-9469
pISSN - 2049-9450
DOI - 10.3892/mco.2021.2403
Subject(s) - carboplatin , medicine , cetuximab , neutropenia , common terminology criteria for adverse events , head and neck cancer , toxicity , regimen , gastroenterology , cancer , surgery , chemotherapy , colorectal cancer , cisplatin